Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI 517 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MEDI517 |
| 2 | ACTIVE_COMPARATOR | Aluminum hydroxide |
| Name | Type | Description |
|---|---|---|
| MEDI 517 | BIOLOGICAL | Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant. |
| Aluminum hydroxide | OTHER | Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL. |
Inclusion Criteria: * Female * 18 through 30 years of age (must not have reached the 31st birthday) * Unless previously surgically sterilized, agrees to use an effective method of birth control (e.g., abstinence, intrauterine contraceptive device, oral contraceptives, diaphragm or condom in combina...
MEDI 517 is an investigational monoclonal antibody being developed by AstraZeneca PLC (AZN). It is currently in Phase 1 clinical development. The drug has been studied in healthy adult female volunteers, with one completed trial involving 60 participants.
MEDI 517 is being studied for use in healthy individuals. Specifically, the completed Phase 1 trial evaluated the safety and immunogenicity of MEDI-517P in healthy adult female volunteers who were HPV-16 or HPV-18 DNA positive. The drug is still in clinical development and is not approved.
MEDI 517 is developed by AstraZeneca PLC, a biopharmaceutical company traded under the ticker AZN. AstraZeneca is conducting clinical trials to evaluate the safety and immunogenicity of this investigational monoclonal antibody in healthy volunteers.
MEDI 517 is in Phase 1 clinical development. The drug is investigational and has not been approved. One Phase 1 trial has been completed, which enrolled 60 healthy adult female volunteers who were HPV-16 or HPV-18 DNA positive.
MEDI 517 has one completed clinical trial, NCT00263744, titled 'Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive.' This Phase 1 trial enrolled 60 healthy female volunteers aged 18 years and older.